Business NewsPR NewsWire • Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®

Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®

Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®

DUBLIN, Aug. 9, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has entered into a licensing agreement with a subsidiary of Merck & Co, Inc., Kenilworth, NJ, USA for the exclusive rights in the United States to pursue regulatory approval for a...

View More : https://www.prnewswire.com:443/news-releases/perrigo-expands-otc-growth-strategy-with-rx-to-otc-switch-licensing-for-nas...
Releted News by prnewswire
Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®
Perrigo Announces Plan To Separate Prescription Pharmaceuticals Business
Perrigo Company plc Reports Second Quarter 2018 Financial Results
Pivot Signs Letter of Intent With Pharmaflorx For Supply Of Cannabis Oils And Isolates Minimum of 1,000 KG/Annually For Use In Pivot's Product Pipeline